Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.

Adult Aged Aged, 80 and over Antineoplastic Agents / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Breast Neoplasms / drug therapy Drug Administration Schedule Female Humans Middle Aged Retrospective Studies Survival Rate Treatment Outcome

Breast cancer Cyclophosphamide Methotrexate Metronomic chemotherapy Vinorelbine

Journal

Breast (Edinburgh, Scotland)

ISSN: 1532-3080

Titre abrégé: Breast

Pays: Netherlands

ID NLM: 9213011

Informations de publication

Date de publication:
Dec 2019

Historique:

received: 05 03 2019

revised: 24 07 2019

accepted: 29 07 2019

pubmed: 31 8 2019

medline: 11 4 2020

entrez: 31 8 2019

Statut: ppublish

Résumé

Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3-10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8-11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3-15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.

Identifiants

DOI: 10.1016/j.breast.2019.07.006 PMID: 31470257

pubmed: 31470257

pii: S0960-9776(19)30535-1

doi: 10.1016/j.breast.2019.07.006

pii:

doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

Pagination

7-16

Investigateurs

F Cicchiello (F)

F Riva (F)

I Vallini (I)

M Mazza (M)

C Bonfadini (C)

E Bordin (E)

M Canicattì (M)

F Cappuccio (F)

E Collovà (E)

C De Angelis (C)

R Desorte (R)

S Donati (S)

G Drudi (G)

D Galanti (D)

C Mocerino (C)

L Orlando (L)

B Pellegrino (B)

L Pizzuti (L)

C Ridolfi (C)

A Rocca (A)

D Sarti (D)

I Spagnoletti (I)

N Tinari (N)

A Vandone (A)

L Vizzini (L)